We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE...
="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksDate of Notice03/11/2024ATTENTION: The person for whose account the securities to which this notice relates are...
As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. 333- UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13A-16 OR 15D-16 UNDERTHE SECURITIES EXCHANGE ACT...
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
ZUG, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13A-16 OR 15D-16 UNDERTHE SECURITIES EXCHANGE ACT...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.89 | -7.56 | 25 | 25.8039 | 20.5001 | 41932 | 23.11299278 | CS |
4 | -1.17 | -4.81878088962 | 24.28 | 27.464 | 20.5001 | 77258 | 24.07213688 | CS |
12 | -2.11 | -8.36637589215 | 25.22 | 33 | 20.5001 | 111336 | 27.59274912 | CS |
26 | 1.95 | 9.21550094518 | 21.16 | 33 | 15 | 112892 | 25.25923122 | CS |
52 | 15.69 | 211.455525606 | 7.42 | 33 | 7.0001 | 77016 | 22.82343669 | CS |
156 | -2.89 | -11.1153846154 | 26 | 33 | 1.77 | 190316 | 12.61628913 | CS |
260 | -1.89 | -7.56 | 25 | 42.86 | 1.77 | 189471 | 13.37931105 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions